Assessing the effectiveness of targeted agents in adjuvant therapy for patients with metastatic colorectal cancer undergoing surgical resection: a retrospective cohort study.
Yi-Chia SuChih-Chien WuYu-Hsun ChenChien-Chou SuYu-Ching ChangMeng-Che HsiehYea-Huei Kao YangPublished in: Therapeutic advances in medical oncology (2024)
Adjuvant chemotherapy plus TAs may improve survival in patients with initially unresectable tumors who underwent conversion surgery following neoadjuvant therapy with TAs, especially in those who respond well to the targeted therapy. Our study underscores the importance of stratifying patients with mCRC based on tumor resectability when selecting the adjuvant therapy regimen.
Keyphrases
- metastatic colorectal cancer
- locally advanced
- minimally invasive
- rectal cancer
- randomized controlled trial
- lymph node
- coronary artery bypass
- cancer therapy
- squamous cell carcinoma
- stem cells
- drug delivery
- acute coronary syndrome
- surgical site infection
- bone marrow
- free survival
- atrial fibrillation
- percutaneous coronary intervention